These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 9723424

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Placebo-controlled study of a humanized anti-TAC monoclonal antibody in dual therapy for prevention of acute rejection after renal transplantation.
    Charpentier B, Thervet E.
    Transplant Proc; 1998 Jun; 30(4):1331-2. PubMed ID: 9636541
    [No Abstract] [Full Text] [Related]

  • 4. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation.
    Bumgardner GL, Hardie I, Johnson RW, Lin A, Nashan B, Pescovitz MD, Ramos E, Vincenti F, Phase III Daclizumab Study Group.
    Transplantation; 2001 Sep 15; 72(5):839-45. PubMed ID: 11571447
    [Abstract] [Full Text] [Related]

  • 5. Daclizumab rapidly saturates interleukin-2 receptor-alpha (CD25) on lymph node lymphocytes in children.
    Savo AM, Book BK, Henson S, Hakimi J, Pescovitz MD.
    Transplant Proc; 1999 Sep 15; 31(1-2):1182-3. PubMed ID: 10083528
    [No Abstract] [Full Text] [Related]

  • 6. Interleukin-2R antagonists in the prevention of acute rejection in living donor transplantation.
    Ivanovski N, Popov Z, Kolevski P, Cakalaroski K, Spasovski G, Sikole A, Paneva-Masin J.
    Transplant Proc; 2001 Sep 15; 33(7-8):3203-4. PubMed ID: 11750374
    [No Abstract] [Full Text] [Related]

  • 7. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
    Nashan B, Light S, Hardie IR, Lin A, Johnson JR.
    Transplantation; 1999 Jan 15; 67(1):110-5. PubMed ID: 9921806
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A, Arnol M, Omahen K, Oblak M, Vidan-Jeras B, Kmetec A, Bren AF.
    Transplantation; 2010 Apr 27; 89(8):1022-7. PubMed ID: 20075788
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Daclizumab to prevent acute rejection in renal transplantation.
    Abramowicz D.
    N Engl J Med; 1998 Jun 04; 338(23):1700-1. PubMed ID: 9616069
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups.
    Ekberg H, Bäckman L, Tufveson G, Tydén G.
    Transplant Proc; 1999 Jun 04; 31(1-2):267-8. PubMed ID: 10083102
    [No Abstract] [Full Text] [Related]

  • 16. Daclizumab in live donor renal transplantation.
    Iverson AJ, Vick SC, Sarnacki CT, Wright FH.
    Transplant Proc; 2000 Jun 04; 32(4):790-2. PubMed ID: 10856587
    [No Abstract] [Full Text] [Related]

  • 17. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.
    Wiseman LR, Faulds D.
    Drugs; 1999 Dec 04; 58(6):1029-42. PubMed ID: 10651389
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Zenapax versus OKT-3 prophylaxis in immunologically high-risk kidney transplant recipients.
    Lácha J, Símová M, Nosková L, Teplan V, Vítko S.
    Transplant Proc; 2001 May 04; 33(3):2273-4. PubMed ID: 11377526
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.